Mark Entwistle
President at Chibas Consulting, Inc.
Mark Entwistle active positions
| Companies | Position | Start | End |
|---|---|---|---|
| Chibas Consulting, Inc. | Director/Board Member | 2011-01-17 | - |
| President | 2011-01-13 | - |
Career history of Mark Entwistle
Former positions of Mark Entwistle
| Companies | Position | Start | End |
|---|---|---|---|
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Director/Board Member | 1997-10-08 | - |
Statistics
International
| United Kingdom | 2 |
| Canada | 2 |
Operational
| Director/Board Member | 2 |
| President | 1 |
Sectoral
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
| Chibas Consulting, Inc. |
- Stock Market
- Insiders
- Mark Entwistle
- Experience
